The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Argus Research on November 20, 2025. The analyst firm set a price target for $68.00 expecting TECH to rise to within 12 months (a possible 15.86% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Bio-Techne (NASDAQ:TECH) was provided by Argus Research, and Bio-Techne maintained their buy rating.

The last upgrade for Bio-Techne Corp happened on September 3, 2025 when RBC Capital raised their price target to $73. RBC Capital previously had a sector perform for Bio-Techne Corp.

The last downgrade for Bio-Techne Corp happened on April 9, 2025 when Keybanc changed their price target from N/A to N/A for Bio-Techne Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Techne, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Techne was filed on November 20, 2025 so you should expect the next rating to be made available sometime around November 20, 2026.

While ratings are subjective and will change, the latest Bio-Techne (TECH) rating was a maintained with a price target of $65.00 to $68.00. The current price Bio-Techne (TECH) is trading at is $58.69, which is out of the analyst’s predicted range.